Smart Medicine: Verification Opinions of the Compensation and Assessment Committee on Adjusting the 2025 Restricted Stock Incentive Plan
Remuneration and Appraisal Committee of Smart Medical Technology Co., Ltd.
Verification Opinions on Adjustments to the 2025 Restricted Stock Incentive Plan
The Remuneration and Assessment Committee of Ruizhi Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") has made adjustments to the company in 2025 in accordance with the relevant laws, regulations, rules and normative documents such as the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Measures for the Administration of Equity Incentives for Listed Companies, the Stock Listing Rules of the Shenzhen Stock Exchange GEM, the Self-Regulatory Guidelines for Companies Listed on the GEM Market of the Shenzhen Stock Exchange No. 1 - Business Processing, and the Articles of Association of the Ruizhi Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Articles of Association"). The matters under the restricted stock incentive plan were verified in 2017, and the verification opinions were as follows:
The company has adjusted some assessment indicators of the 2025 Restricted Stock Incentive Plan this time. The review process is legal and compliant, and complies with relevant laws, regulations and normative documents such as the "Measures for the Administration of Equity Incentives for Listed Companies" and the relevant provisions of the "2025 Restricted Stock Incentive Plan (Draft)". This adjustment is based on the company's actual operating conditions and adjustments to the internal assessment mechanism, which will help ensure the smooth implementation of the company's 2025 Restricted Stock Incentive Plan, further improve the corporate governance structure, and improve the company's incentive mechanism. This adjustment will not have a substantial impact on the company's financial status and operating results. It will not result in accelerating the exercise of options or early lifting of sales restrictions or reducing the exercise price or grant price. It will be conducive to the company's sustainable development and will not harm the interests of the company and all shareholders.
In summary, we unanimously agree that the company will adjust matters related to the 2025 restricted stock incentive plan.
Smart Pharmaceutical Technology Co., Ltd.
Remuneration and Appraisal Committee
February 27, 2026